Moderna

MRNA

Market cap $26.7B

Moderna (MRNA) reached $66.98 at the closing of the latest trading day, reflecting a -1.89% change compared to its last close.

Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.

Moderna said on Thursday it has secured a European Commission contract to ​supply its respiratory syncytial virus vaccine ‌to six countries in the region.

CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second quarter 2026 financial results, and provide a corporate update.

Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the appointment of Michael McDonnell to its Board of Directors, effective July 8, 2026. Mr. McDonnell will also serve on the Board's Audit Committee.

Moderna is no longer just a COVID-19 vaccine company. A growing pipeline could fuel long-term revenue growth.

Moderna (MRNA) closed at $81.76 in the latest trading session, marking a +2.51% move from the prior day.

Each of these biotech players has reached an important turning point. Recent drug approvals could supercharge the performance of one in particular.

Tom Yeung here with your Sunday Digest . In the days following its IPO, Space Exploration Technologies Corp. ( SPCX ) surged 25%, rewarding early investors and turning its owner, Elon Musk, into a trillionaire.

An FDA advisory panel voted 9-0 that Moderna's mRNA flu vaccine's benefits outweigh its risks. A final approval decision is expected by Aug. 5.